Executive Summary
What this business is
Customers
Cash-paying US adults (58% of portal visits) seeking affordable compounded GLP-1 weight-loss treatments and longevity peptides without insurance hassles.
Offering
IntakeQ-hosted telehealth intake forms and patient portal (/portal) powering Fifty 410's cash-pay compounded GLP-1 weight-loss prescriptions (semaglutide/tirzepatide via 503B pharmacies) and upcoming hair-loss, Sermorelin, and NAD+ lines.
Business model
Asset-light cash-pay telehealth model pairing paid social acquisition with off-the-shelf IntakeQ EHR infrastructure and outsourced 503B pharmacy fulfillment.
Pricing
Compounded GLP-1 plans starting at $199/mo (tirzepatide from $133/mo or $399 for 3 months; high-dose at $183/mo; third-party review cites $99/mo entry).
- Takeoff mode
- GLP-1 Compounding Tailwind
- GLP-1 Pricing
- From $133-$199/mo ($399 / 3 mos)
Branded GLP-1 shortages and $1,000+/mo insurance barriers opened a massive cash-pay market for compounded alternatives. Fifty 410 seized that wave by staying ultra-lean on software: instead of building HIPAA-compliant EHRs from scratch, it runs all intake and refill workflows on fifty410.intakeq.com, connects patients to licensed doctors, and outsources fulfillment to independent 503B pharmacies.
Priced at $133/mo (bundled as $399 for 3 months on tirzepatide), Fifty 410 undercuts typical $300+/mo telehealth clinics. Selling multi-month bundles upfront cushions paid-ad CAC while requiring every patient to return to fifty410.intakeq.com/portal for clinical follow-ups and dose titrations—driving high refill retention.
LinkedIn lists Fifty 410 as founded in 2023 in Dallas, TX (Trustpilot address in nearby Prosper, TX) with 11–50 employees (12 listed on LinkedIn, actively hiring a CMO), though founders remain unnamed. Registering fifty410.com on Oct 12, 2023 and launching a complete site by Nov 1, 2023 positioned it squarely ahead of the 2024 GLP-1 boom.